A vitamin B12 conjugate of exendin-4 improves glucose tolerance without associated nausea or hypophagia in rodents.

Elizabeth G Mietlicki-BaaseClaudia G LiberiniJayme L WorkingerRon L BonaccorsoTito BornerDavid J ReinerKieran Koch-LaskowskiLauren E McGrathRinzin LhamoLauren M SteinBart C De JongheGeorge G HolzChristian L RothRobert P Doyle Matthew R Hayes

Published in: Diabetes, obesity & metabolism (2018)

These novel findings highlight the potential clinical utility of B12-Ex4 conjugates as possible future T2DM therapeutics with reduced incidence of adverse effects.

Keyphrases

cancer therapy
risk factors
current status
small molecule
chemotherapy induced
drug delivery
glycemic control
type diabetes
metabolic syndrome
risk assessment
climate change
insulin resistance
weight loss